Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116245 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Tianxiao Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Zhejiang-Hong Kong Joint Laboratory of Liver and Spl…. Hauptthemen laut MEDLINE: Aldehydes, Hydrogen Sulfide, Placenta, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Zhejiang Province Natural Science Foundation, Zhejiang Chinese Medical University.
Abstract (Originalsprache)
This study aims to investigate the molecular mechanisms by which 4-hydroxynonenal (4-HNE) regulates hydrogen sulfide (H₂S)-producing enzymes, mediating the pathogenesis of metabolic dysfunction-associated fatty liver disease (MAFLD) during pregnancy, thereby offering novel molecular targets for early diagnosis and intervention of related disorders. By establishing a MAFLD pregnant mouse model, we comprehensively examined the regulatory effects of 4-HNE on placental function and its interaction with the H₂S system. We found that MAFLD pregnant mice exhibited significant glucose metabolic disorders, hepatic steatosis, and placental damage. Mechanistically, 4-HNE disrupts H₂S biosynthesis, thereby impairing its inhibitory effect on the inflammasome pathway while simultaneously activating inflammatory cascades. This synergistic action exacerbates placental pathological damage, manifesting as abnormal vascular function and impaired materno-fetal exchange. Notably, exogenous H₂S intervention partially reversed 4-HNE-induced toxicity, suggesting the therapeutic potential of targeting this pathway. These findings demonstrate the pivotal role of the "4-HNE-H₂S-NLRP3" regulatory axis in MAFLD-associated placental injury, providing novel mechanistic insights and potential therapeutic targets for pregnancy complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China; Zhejiang-Hong Kong Joint Laboratory of Liver and Spleen Simultaneous Treatment in Traditional Chinese Medicine, Zhejiang,…
- Department of Endocrinology, No. 903 Hospital of PLA Joint Logistic Support Force, Hangzhou, Zhejiang 310013, China.
- School of Integrated Traditional Chinese and Western Medicine, Chongqing University of Chinese Medicine, Chongqing 402760, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metab…
Förderung
- Zhejiang Province Natural Science Foundation
- Zhejiang Chinese Medical University
Zitieren
APA
Hu, T., Qi, J., Xu, Y., He, J., Tan, Q., Hao, J., Wang, J., Hong, J., Wang, J., Chen, L., & Dou, X. (2026). Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116245
Vancouver
Hu T, Qi J, Xu Y, He J, Tan Q, Hao J, et al. Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116245
BibTeX
@article{Hu2026,
author = {Hu, Tianxiao and Qi, Jiayu and Xu, Yinuo and He, Jia and Tan, Qingying and Hao, Jie and Wang, Jing and Hong, Jiewei and Wang, Jianwei and Chen, Lin and Dou, Xiaobing},
title = {Targeting the 4-HNE–H₂S pathway as a therapeutic strategy for placental injury in pregnancy with MAFLD},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116245}
}
EUVIMED